Amphastar Pharmaceuticals, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2017-09-30 was -$23.00K, a 100.16% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2016-09-30 was $14.33M, a 1656.25% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2016-06-30 was $3.15M, a 67.91% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2016-03-31 was $104.00K, a 88.57% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2015 was $13.50M, a 2264.62% increase from fiscal 2014.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2014 was $571.00K, a 938.18% increase from fiscal 2013.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2013 was $55.00K, a 83.48% decline from fiscal 2012.
- Amphastar Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2012 was $333.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2017-09-30 | -$23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | |
| 2016-09-30 | $14.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $19.55M derived: sum of 4 quarters · filed 2016-11-09 |
| 2016-06-30 | $3.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $6.03M derived: sum of 4 quarters · filed 2016-08-09 |
| 2016-03-31 | $104.00K 10-Q · filed 2016-05-10 | $12.70M derived: sum of 4 quarters · filed 2016-05-10 |
| 2015-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $13.50M 10-K · filed 2016-03-15 |
| 2015-09-30 | $816.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $11.41M derived: sum of 4 quarters · filed 2016-03-15 |
| 2015-06-30 | $9.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $10.72M derived: sum of 4 quarters · filed 2016-03-15 |
| 2015-03-31 | $910.00K 10-Q · filed 2015-05-14 | |
| 2014-12-31 | -$130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $571.00K 10-K · filed 2016-03-15 |
| 2014-09-30 | $130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | |
| 2013-12-31 | $55.00K 10-K · filed 2016-03-15 | |
| 2012-12-31 | $333.00K 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |